EXXELL BIO, INC. TEAMS WITH GENEVA IN VACCINE DEVELOPMENT COLLABORATION

PRESS RELEASE

16 November 2017

Exxell BIO, Inc. announces collaboration The Geneva Foundation, Thomas Jefferson University, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), IDT Biologika, and The Infectious Disease Research Institute (IDRI).

Exxell BIO, Inc. joins consortium in collaboration with Geneva, Thomas Jefferson University, USAMRIID, IDT Biologika, and IDRI for preparation and vaccine formulation testing for protection against the Ebola, Sudan, Marburg, and Lassa fever viruses.

These deadly viruses, categorized as hemorrhagic fever viruses, display varying symptoms that typically appear 2-21 days after exposure, and can include symptoms of fever, fatigue, and muscular pain, progressing in severity to include uncontrollable internal and external bleeding; and commonly result in a high mortality rate.

The development and testing of a tetravalent vaccine against these viruses is a primary goal of this collaboration, and would be the first of its kind. Principal Investigator Matthias Schnell, Ph.D., Professor and Chair of Microbiology and Immunology and Director of Jefferson Vaccine Center at the Sidney Kimmel Medical College at Thomas Jefferson University stated that, “our approach is to create a broad scope of coverage with a tetravalent vaccine – one that covers four of these deadly viral diseases.”

Geneva’s support of this program will continue the organization’s work in the field of infectious disease research, one of Geneva’s primary areas of focus. Geneva remains committed to offering researchers and collaborators a superior level of service and expertise in our support and management of federally-funded research and industry-sponsored clinical trials.

Excell BIO, Inc. Geneva Press Release, 16 November 2017

About Thomas Jefferson University Thomas Jefferson University is a private university in Philadelphia, Pennsylvania, United States. Its Medical School is the Sidney Kimmel Medical College.  The Principal Investigator of this contract is Matthias Schnell, Ph.D., Professor and Chair of Microbiology and Immunology and Director of the Jefferson Vaccine Center at the Sidney Kimmel Medical College at Thomas Jefferson University.

About IDT Biologika GmbH IDT Biologika, headquartered in Dessau-Rosslau, Germany, is an innovative, privately-held life science company with more than 94 years of expertise in Research, Development and Manufacturing of biologics and vaccines for the global protection of humans and animals.

About IDRI The Infectious Disease Research Institute (IDRI) is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases. For more information, visit www.idri.org.

About United States Army Medical Research Institute of Infectious Diseases USAMRIID’s mission is to provide leading edge medical capabilities to deter and defend against current and emerging biological threat agents. Research conducted at USAMRIID leads to medical solutions—vaccines, drugs, diagnostics, and information—that benefit both military personnel and civilians. For more information, visit www.usamriid.army.mil

About The Geneva Foundation The Geneva Foundation (Geneva) is a 501c3 non-profit organization headquartered in Tacoma, WA. Established in 1993, Geneva advances military medicine by delivering full spectrum scientific, technical, and program management expertise in the areas of federal grants, industry-sponsored clinical trials, federal contracts, and event management. Please visit www.genevaUSA.org for more information.

 


FIND MORE news and events »